Daltons ownership percentage dropped the past 3-months from June 30th--2026 (55.61%) to Sept 30th-2026 (51.65)--his share count still remains the same (1,303,122,537) Outstanding share count remains the same (2,523,096,680) Check the vendor debt, nothing has been paid on the debt in the past (6) years yet fabricated debt goes up ever quarter, this is how he has kept UNVC trading at the Shell Risk Pink Tier. At some point regulators do step in-Tic-Toc.
Dr. David Dalton-Chair/CEO @ UNIVEC,INC. (UNVC) 4 Halls of Fame-“Senatorial” Medal of Freedom - Emeritus Archon, Banner Honor Veteran- IFAH Top 100 Worldwide- Founder NMHA and NHA.Pharma-Telehealth-Mental -Metaverse-AI- UNIVECHEALTH.COM
3mo
Univec Inc. (UNVC) otcMarkets
NDC ( National Drug Code) provides the identification for Insurance payment for patient care.
Process is going well expected soon.
Color is Green as in Money.
If process is going well then there should be a record: None exist, about 4 weeks is a realistic time frame!!!
Based on public FDA registries (the National Drug Code Directory and NIH DailyMed) and state corporate/pharmacy records, none of the three entities—CentennialRx, 11Three, or Univec (UNVC)—hold active product listings in the FDA NDC Directory. Neither "11Three," "11Three Tech," nor its promoted transdermal patch "Reliefta" has an assigned NDC or active drug listing in the FDA NDC Directory or DailyMed.
On its website (11threetech.com), 11Three does not claim to hold its own FDA labeler code; instead, it explicitly states it relies on "Univec's FDA labeler and PLD [Private Label Distributor] infrastructure, direct eDRLS listing". Furthermore, the consumer site (reliefta.com) markets Reliefta as a hemp/cannabinoid wellness patch (CBD, CBC, CBG, CBN) rather than an FDA-listed pharmaceutical drug.
There is no verified state Board of Pharmacy retail, mail-order, or wholesale distributor licenses registered to Dr. David Dalton's Delaware entity CentennialRx Inc.
Investor Note;
While it is theoretically possible that submissions are being prepared privately, any completed and active product NDC would already appear in the public FDA databases. The continued absence of those NDCs indicates that listings have either not been successfully completed or have not been accepted/published. Additionally, there is no public record of clinical trials having been performed on the RELIEFTA product itself. This information is for discussion purposes only and is not investment advice. Always verify current FDA listings and company filings yourself.
PL